Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 2 Interventional Results available

Tau Imaging of Chronic Traumatic Encephalopathy

NCT02191267
Conditions
Chronic Traumatic Encephalopathy
Interventions
[F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
Radiation · Device · Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

University of Pittsburgh Brain Health Initiative

NCT04708613
Conditions
Traumatic Brain Injury
Interventions
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451
Diagnostic Test · Drug
Lead sponsor
David Okonkwo, MD, PhD
Other
Eligibility
29 Years to 59 Years · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer Disease
Interventions
F 18 T807 Flortaucipir
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PET Tau - Neurodegenerative Disease Imaging

NCT03143374
Conditions
Neurodegenerative Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Primary Progressive Aphasia With Suspected Alzheimer's Disease
Interventions
18F-AV-1451, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Completed Phase 3 Interventional Results available

18F-AV-1451 Autopsy Study

NCT02516046
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Los Gatos, California • Newport Beach, California + 23 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 16 more
Completed Phase 1 Interventional Accepts healthy volunteers

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

NCT02850146
Conditions
Cognition Disorders
Interventions
18F-AV-1451
Drug
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New Haven, Connecticut • The Villages, Florida + 4 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

NCT03809351
Conditions
Alzheimer Disease
Interventions
[F-18]AV-1451-PET
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Brain Imaging, Whole Body Imaging
Interventions
18F-FDG, 18F-AV1451, Siemens E7 Reconstruction Tool
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

NCT02676843
Conditions
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies
Interventions
18F-AV-1451
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972
Conditions
Cognitive Decline
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Conditions
Alzheimer Disease
Interventions
flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Tau PET Imaging in the NACC Study Cohort

NCT03189485
Conditions
Normal Controls, MCI
Interventions
the radiotracer 18F-AV-1451
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri